VII

Euler Hermes Is Now Allianz Trade

Retrieved on: 
Monday, March 28, 2022
Finance, Banking, Professional Services, Other Professional Services, Insurance, Allianz, Heart, VIII, XI, III, Growth, Mortality, Board, VII, Excess, CEO, Intelligence, VI, Knowledge, Ecosystem, Euler Hermes, AA, Disease, Solution, IX, Awareness, Risk management, Retail, Bank

Today marks a new chapter in our story: Euler Hermes, the world leader in trade credit insurance, becomes Allianz Trade a natural move as we have been fully part of the Allianz Group since 2018.

Key Points: 
  • Today marks a new chapter in our story: Euler Hermes, the world leader in trade credit insurance, becomes Allianz Trade a natural move as we have been fully part of the Allianz Group since 2018.
  • Chris Townsend, member of the Board of Management of Allianz SE, adds: We are excited to see Euler Hermes become Allianz Trade and are convinced that the change will bring about many benefits in terms of awareness, business development, growth and innovation.
  • We predict trade and credit risk today, so companies can have confidence in tomorrow
    Allianz Trade is the global leader in trade credit insurance and a recognized specialist in the areas of surety, collections, structured trade credit and political risk.
  • Allianz Trade is the trademark used to designate a range of services provided by Euler Hermes.

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 18, 2022
Risk, LinkedIn, Tears, NASDAQ, COL7, Degenerative disease, Lung, Epidermis, Suma, European Medicines Agency, KRYS, VII, Skin, Dermis, Research, DEB, Dermatology, Food, Tissue, Â, Priority, COL7A1, Finger, Safety, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Concha bullosa, GLOBE, American Academy, EMA, The, Squamous cell carcinoma, Blister, Fibrosis, Trauma, Awareness, Research and development, FDA, Patient, Pharmaceutical industry

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022American Academy of Dermatology Annual Meeting, taking placeMarch 25-29inBoston, Mass.

Key Points: 
  • PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022American Academy of Dermatology Annual Meeting, taking placeMarch 25-29inBoston, Mass.
  • This is a terrific opportunity to raise awareness of DEB among the dermatology community and convey the need for a therapeutic option that addresses the underlying genetic cause of the disease.
  • The lack of functional anchoring fibrils in DEB patients leads to extremely fragile skin that blisters and tears from minor friction or trauma.
  • The FDA has also granted B-VECfast track designation and rare pediatric designation for the treatment of DEB.

physIQ and CellCarta Collaborate to Accelerate a More Precise, Personalized Approach to Vaccine Development

Retrieved on: 
Thursday, March 17, 2022
Professional Services, Mobile, Wireless, Other Science, Research, Science, Nursing, Other Health, FDA, General Health, Pharmaceutical, Other Education, Medical Devices, Education, Infectious Diseases, Other Consumer, Other Technology, Hospitals, Women, Software, Seniors, Clinical Trials, Cardiology, Men, Biotechnology, Data Management, Technology, Health, Other Professional Services, Consumer, Consulting, LinkedIn, Behavior, Principal, VIII, Vaccination, ECG, Â, Health, Clinical trial, Multimedia, VII, Vital signs, Vaccine, Genomics, Sleep, Physiology, Precision medicine, MD, Immune system, Artificial intelligence, Twitter, Inflammation, COVID-19, Skin temperature, FDA, Proteomics, Patient, Artificiality, Collection, Pharmaceutical industry, physIQ, CellCarta, PHYSIQ, CELLCARTA

View the full release here: https://www.businesswire.com/news/home/20220317005256/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220317005256/en/
    physIQ and CellCarta launch study to detect vaccine side effects early and help pharma companies potentially bring new vaccinations to market faster.
  • The study will use blood samples and medical-grade biosensors to continuously monitor and capture remote patient physiology data 24/7.
  • Such changes in physiology and behavior can be detected within hours after a vaccine is administered and can be correlated to long-lasting immune responses.
  • Our goal is to provide tools that help accelerate the therapeutic development of personalized vaccine regimens by looking at the full immune response.

Footprint Wins Double Awards from Flexographic Technical Association

Retrieved on: 
Monday, March 14, 2022
Food, Beverage, Manufacturing, Environment, Retail, Packaging, Securities Act of 1933, Risk, Communication, Registration statement, Private Securities Litigation Reform Act, VIII, The Gores Group, Form, Atmosphere, FTA, Industry, THE, Register, Name, CRIMINAL, Failure, LLC, Multimedia, Plastic, Reading, Special, Water, SEC, VII, Review, NASDAQ, Mac n' Cheetos, Time, Attention, PIPE, Food chain, Intel, Person, CNBC, U.S. Securities and Exchange Commission, Sale, Solution, Holding, Forward-looking statement, Nasdaq, Cheese, Prospectus, Acquisition, Intention, Technology, Printing, Proxy, Goal, Bottled water, Risk management, Audit, Security (finance), Footprint

Footprint, a global materials science technology company focused on creating a healthy planet, won two awards from the Flexographic Technical Association (FTA) celebrated at their annual awards banquet last night.

Key Points: 
  • Footprint, a global materials science technology company focused on creating a healthy planet, won two awards from the Flexographic Technical Association (FTA) celebrated at their annual awards banquet last night.
  • View the full release here: https://www.businesswire.com/news/home/20220314005247/en/
    Footprint was honored with the Flexographic Technical Associations Sustainability Excellence Award and the Excellence in Flexographic Printing Award for its shelf-stable cup and print-to-fiber technology, a flexographic print process on molded fiber cups.
  • The FTA receives hundreds of competitive award entries each year, which are individually evaluated by qualified flexographic industry members.
  • Neither Gores Holdings VIII nor Footprint gives any assurance that either Gores Holdings VIII or Footprint will achieve its expectations.

Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB

Retrieved on: 
Monday, March 14, 2022
People, Nasdaq, Drug Quality and Security Act, Safety, Concha bullosa, Securities Act of 1933, Company, U.S. Securities and Exchange Commission, FDA, Cell, Annual report, UMass Memorial Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Pain, Stanford University Medical Center, Sanfilippo, Connective tissue, Securities Exchange Act of 1934, Keratinocyte, Data analysis, Stanford University, Skin, GLOBE, Patient, Wound healing, Security (finance), Week, Terminology, Technology, COVID-19, MPS, AAV, CA, Epidermolysis bullosa dystrophica, Therapy, COL7A1, Food, VII, Medical device, Pharmaceutical industry, University of Massachusetts, RDEB

NEW YORK and CLEVELAND, March 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL study.

Key Points: 
  • NEW YORK and CLEVELAND, March 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL study.
  • Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients.
  • The EB-101 VIITAL study is a randomized clinical trial with target enrollment of at least 10 to 15 RDEB patients with approximately 36 large, chronic wound sites treated in total.
  • Abeona produces EB-101 for the VIITAL study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, Ohio.

LTV SaaS Growth Fund Reports 2021 Financial Results

Retrieved on: 
Wednesday, February 16, 2022
LTV, VI, Growth, Investment, Multimedia, LTM, View, Database, MRR, General partnership, Free Enterprise Fund v. Public Company Accounting Oversight Board, VII, Software as a service, Acquisition, Food delivery, Bank

NEW YORK, Feb. 16, 2022 /PRNewswire/ -- With three active funds (collectively " LTV SaaS Growth Fund "), and unprecedented insight into the small- and mid-cap SaaS ecosystem, LTV SaaS Growth Fund has continued to deliver profitable growth at scale.

Key Points: 
  • NEW YORK, Feb. 16, 2022 /PRNewswire/ -- With three active funds (collectively " LTV SaaS Growth Fund "), and unprecedented insight into the small- and mid-cap SaaS ecosystem, LTV SaaS Growth Fund has continued to deliver profitable growth at scale.
  • The fund deployed all capital by August 2021, with combined revenues growing c.46.2% from August to December 2021.
  • LTV SaaS Growth Fund is a U.S. investment fund focused on small- and mid-cap SaaS and software investments in privately held businesses.
  • LTV SaaS Growth Fund has exclusive access to the world's largest database of private acquisition data for SaaS businesses in the $1MM $50MM range, providing a significant strategic advantage to its valued investors.

Bioceres Crop Solutions Reports Fiscal Second Quarter 2022 Financial and Operational Results

Retrieved on: 
Thursday, February 10, 2022
Agriculture, Natural Resources, Manufacturing, Environment, Chemicals, Plastics, Shift, NASDAQ, Agriculture, Growth, Â, International Financial Reporting Standards, Doctor of Philosophy, Acquisition, Solution, Innovation, SG, Company, Marketing, Financial result, Yoy, University, VII, State university system, EBITDA, International, Genetics, Carbon, LTM, Income, TMG, Certification, MBA, Security (finance)

Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported financial results for the second quarter 2022, ended December 31, 2021.

Key Points: 
  • Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has reported financial results for the second quarter 2022, ended December 31, 2021.
  • Financial results are expressed in US dollars and are presented in accordance with International Financial Reporting Standards.
  • The combined growth in Europe and the United States reached 146% YoY during the quarter.
  • Comparable Gross Profit for the quarter was up 69%, compared to the year-ago quarter, reaching $42.2 million.

High School Researcher Finds Mechanism That May Prevent Metastatic Cancer

Retrieved on: 
Monday, January 31, 2022
Magnet, EGCG, Breast, VII, Georgia World Congress Center, Society for Science, Secondary school, Public, Research, Cancer, Program, Litt, Student, Congress Center, Epithelium, Regeneron Pharmaceuticals, Pharmaceutical industry, Technology, Middle school, Mathematics, ISEF, Science

This is based upon evidence that the antioxidant, EGCG, binds to a protein responsible for cancer becoming more aggressive and spreading.

Key Points: 
  • This is based upon evidence that the antioxidant, EGCG, binds to a protein responsible for cancer becoming more aggressive and spreading.
  • Stephen is no stranger to science fairs and has been competing since first grade and has been focused on his cancer research since sixth grade.
  • The research started when Litt was in Middle School and used planarian worms as a model for cancer treatment.
  • Subsequently, Litt was able to work with human breast and cervical cancer cells and prove that EGCG killed the cancer cells without harm to normal human epithelial cells.

High School Researcher Finds Mechanism That May Prevent Metastatic Cancer

Retrieved on: 
Monday, January 31, 2022
Magnet, EGCG, Breast, VII, Georgia World Congress Center, Society for Science, Secondary school, Public, Congress, Research, Cancer, Program, Litt, ISEF, Student, GLOBE, Epithelium, Regeneron Pharmaceuticals, Coffee, Technology, Middle school, Mathematics, Science

At the fair, Litt earned the Top Overall Project designation and a coveted spot as a finalist at the Regeneron International Science and Engineering Fair (ISEF) for a third time during his High School career.

Key Points: 
  • At the fair, Litt earned the Top Overall Project designation and a coveted spot as a finalist at the Regeneron International Science and Engineering Fair (ISEF) for a third time during his High School career.
  • ISEF is to be held in Atlanta, Georgia from May 7-13, 2022 at the Georgia World Congress Center.ISEF, a program of Society for Science & the Public, is the world's largest international pre-college science competition.
  • The research started when Litt was in Middle School and used planarian worms as a model for cancer treatment.Subsequently, Litt was able to work with human breast and cervical cancer cells and prove that EGCG killed the cancer cells without harm to normal human epithelial cells.Over the past two years, Litt decided to delve into the molecular level to determine how EGCG may be keeping cancer at bay.
  • Regeneron ISEF unites these top young scientific minds, showcasing their talents on an international stage, where doctoral level scientists review and judge their work.

Champlain Insurance Group Announces A-, VII Rating from AM Best

Retrieved on: 
Friday, January 28, 2022
Growth, Strategic management, Insurance, Assistant, VII, Veteran, General counsel, LLC, Congress, Risk management, Bolam v Friern Hospital Management Committee, GDH, News, Industry, AM Best, CIG, Solution, Management

"Our affiliated program administrator, WestCongress Insurance Services LLC ("West Congress"), produced over $80 Million in gross written premium in 2021 and will experience significant growth in 2022.

Key Points: 
  • "Our affiliated program administrator, WestCongress Insurance Services LLC ("West Congress"), produced over $80 Million in gross written premium in 2021 and will experience significant growth in 2022.
  • We will begin to expeditiously transition that business to Champlain Specialty as market and customer conditions dictate," Mr. Smith continued.
  • Champlain Insurance Group is a specialty, surplus and excess lines insurance enterprise, which through its affiliates, Champlain Specialty Insurance Company and WestCongress Insurance Services LLC, offers primary and excess general liability insurance solutions throughout the United States to niche and underserved market segments where our experience and expertise allow us to tailor insurance products to the needs of our insureds.
  • Champlain Specialty is currently eligible to write business in approximately forty states and is in the process of obtaining eligibility in the remaining states.